Search:
Filter:
Sort:
The advisory committee voted to advance substances that FDA’s own scientists flagged as lacking adequate evidence of safety, efficacy, or quality. Its recommendation will inevitably be interpreted as an endorsement of broader clinical use. It is not.
Fatality reported as the FDA’s Pharmacy Compounding Advisory Committee weighs adding more untested peptides to the compounding list
She was given a dramatic increase in her prescribed dose, a change she questioned, but was told to follow the doctor’s instructions. Despite injecting a smaller amount than directed, she began violently vomiting within hours.
Join us in person in Washington DC on Wednesday July 26, 2026 for Axios Live “Examining Risk and Regulation in the GLP-1 Landscape” Speakers include The Honorable Nikki Budzinski (IL-13), Scott Kahan, M.D., M.P.H., F.T.O.S., Shabbir Imber Safdar, CFE, The Honorable Rudy Yakym (IN-02)
The study found that 91.8% of the platforms issued a prescription. In their questionnaire, which was used on every platorm, 98% asked about medical conditions, 93.9% asked about medications and allergies, and only 55.1% asked about eating disorder history.
The FDA is reconsidering adding a dozen peptides—seven in July; another four next February—to its Section 503A bulk drug substances list after excluding them over safety concerns in 2023. The review is happening at a time when Americans are turning to peptides at an unprecedented rate, driven by grifters in the online wellness space, who push these products for a profit without any clinical evidence they are either safe or effective.
On July 23-24, the FDA will evaluate seven peptides for custom pharmacy compounding. Citing a critical deficit in human safety data, widespread consumer confusion, and systemic supply chain vulnerabilities, PSM urges the committee to block mass compounding and protect patient safety.
The nations first upper payment limit, set to take effect in January 2027, has been temporarily paused. Chief Judge Daniel Domenico said Amgen would face significant and irreparable harm because of the price cap, and found that federal patent law likely preempted a state price cap, reported Reuters.
A Call to Action: Restoring and Strengthening America’s Patient Safety System presents a two pillar system for regulators and lawmakers to preserve the FDAs gold standard.
ADAP Advocacy and the Partnership for Safe Medicines (PSM) issued the following joint statement as a warning to pharmacists that all discounted HIV products bought from online, pharmacy-to-pharmacy (P2P) marketplaces fit the definition of suspect product under U.S. Food and Drug Administration (FDA) guidelines and the Drug Supply Chain Security Act.